



## Clinical trial results:

### A Randomised, Double Blind, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of nasal spray ANTIRIN® and NASIC® in the Treatment of Acute Viral Rhinitis

#### Summary

EudraCT number	2005-005876-33
Trial protocol	CZ
Global end of trial date	17 July 2007

#### Results information

Result version number	v1 (current)
This version publication date	16 July 2016
First version publication date	16 July 2016

#### Trial information

##### Trial identification

Sponsor protocol code	13/05/OXD/TP3
-----------------------	---------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Zentiva k.s
Sponsor organisation address	U kabelovny 130 , Praha 10 - Dolní Měcholupy, Czech Republic, 102 37
Public contact	MUDr. Tomas Hauser, Zentiva k.s., 00420 267243451, Tomas.Hauser@sanofi.com
Scientific contact	MUDr. Tomas Hauser, Zentiva k.s., 00420 267243451, Tomas.Hauser@sanofi.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	17 July 2007
Is this the analysis of the primary completion data?	Yes
Primary completion date	17 July 2007
Global end of trial reached?	Yes
Global end of trial date	17 July 2007
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To determine if the study drug ANTIRIN® is at least as effective (non-inferiority testing) assessed by TNSS changes after 4 days of therapy as the comparative product NASIC® in the treatment of acute viral rhinitis, to compare ANTIRIN® with placebo to proof of its efficacy and to compare NASIC® with placebo to proof assay sensitivity.

Protection of trial subjects:

No specific measurements required

Background therapy:

NA

Evidence for comparator:

NA

Actual start date of recruitment	29 May 2006
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Czech Republic: 221
Country: Number of subjects enrolled	Russian Federation: 32
Worldwide total number of subjects	253
EEA total number of subjects	221

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	253
From 65 to 84 years	0

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

May 29, 2006

13 centres in Czech republic and 2 in Russia

### Pre-assignment

Screening details:

inclusion/exclusion criteria check-list, medical history/ physical examination, laboratory examination: clinical chemistry, urinalysis, haematology, serology

### Period 1

Period 1 title	Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	ANTIRIN

Arm description:

This arm includes patients receiving ANTIRIN as a study medication.

Arm type	Experimental
Investigational medicinal product name	ANTIRIN
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Nasal spray
Routes of administration	Nasal use

Dosage and administration details:

0.1 mg of xylometazolin-hydrochlorid and 5.0 mg of dexpanthenol, 3x1 administration of spray/day into each nostril in horizontal position. 1 administration is one dose of spray into each nostril (0.1 ml, 0.1 g).

<b>Arm title</b>	NASIC
------------------	-------

Arm description:

This arm includes patients receiving NASIC as a study medication.

Arm type	Active comparator
Investigational medicinal product name	NASIC
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Nasal spray
Routes of administration	Nasal use

Dosage and administration details:

0.1 mg of xylometazolin-hydrochlorid and 5.0 mg of dexpanthenol, 3x1 administration of spray/day into each nostril in horizontal position. 1 administration is one dose of spray into each nostril (0.1 ml, 0.1 g).

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

This arm includes patients receiving placebo as a study medication.

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Nasal spray
Routes of administration	Nasal use

Dosage and administration details:

0 mg of xylometazolin-hydrochlorid and 0 mg of dexpanthenol, 3x1 administration of spray/day into each nostril in horizontal position. 1 administration is one dose of spray into each nostril (0.1 ml, 0.1 g).

<b>Number of subjects in period 1<sup>[1]</sup></b>	ANTIRIN	NASIC	Placebo
Started	81	85	84
Completed	81	85	84

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 250 subjects were administered study medication, 3 of original 253 subjects were not included into the study

## Baseline characteristics

### Reporting groups

Reporting group title	ANTIRIN
Reporting group description:	
This arm includes patients receiving ANTIRIN as a study medication.	
Reporting group title	NASIC
Reporting group description:	
This arm includes patients receiving NASIC as a study medication.	
Reporting group title	Placebo
Reporting group description:	
This arm includes patients receiving placebo as a study medication.	

Reporting group values	ANTIRIN	NASIC	Placebo
Number of subjects	81	85	84
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	81	85	84
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	32.827	29.718	29.548
standard deviation	± 12.257	± 10.884	± 10.734
Gender categorical			
Units: Subjects			
Female	46	59	58
Male	35	26	26

Reporting group values	Total		
Number of subjects	250		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	250		

From 65-84 years	0		
85 years and over	0		

Age continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical			
Units: Subjects			
Female	163		
Male	87		

## End points

### End points reporting groups

Reporting group title	ANTIRIN
Reporting group description: This arm includes patients receiving ANTIRIN as a study medication.	
Reporting group title	NASIC
Reporting group description: This arm includes patients receiving NASIC as a study medication.	
Reporting group title	Placebo
Reporting group description: This arm includes patients receiving placebo as a study medication.	

### Primary: TNSS change

End point title	TNSS change <sup>[1]</sup>
End point description:	
End point type	Primary
End point timeframe: data analysed for the whole study period	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: NA	

End point values	ANTIRIN	NASIC	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	81	85	84	
Units: TNSS				
arithmetic mean (standard error)	-4.598 (± 0.237)	-4.612 (± 0.245)	-4.831 (± 0.214)	

### Statistical analyses

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

assessment of the whole study period for each arm

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	10.1
--------------------	------

### Reporting groups

Reporting group title	ANTIRIN
-----------------------	---------

Reporting group description:

This arm includes patients receiving ANTIRIN as a study medication.

Reporting group title	NASIC
-----------------------	-------

Reporting group description:

This arm includes patients receiving NASIC as a study medication.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

This arm includes patients receiving placebo as a study medication.

Serious adverse events	ANTIRIN	NASIC	Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 84 (0.00%)	0 / 86 (0.00%)	0 / 83 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	ANTIRIN	NASIC	Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 84 (15.48%)	8 / 86 (9.30%)	4 / 83 (4.82%)
Cardiac disorders			
Syncope			
subjects affected / exposed	1 / 84 (1.19%)	0 / 86 (0.00%)	0 / 83 (0.00%)
occurrences (all)	1	1	1
Nervous system disorders			
Headache			
subjects affected / exposed	3 / 84 (3.57%)	0 / 86 (0.00%)	1 / 83 (1.20%)
occurrences (all)	4	4	4

Dizziness subjects affected / exposed occurrences (all)	0 / 84 (0.00%) 1	0 / 86 (0.00%) 1	1 / 83 (1.20%) 1
General disorders and administration site conditions Nasal discomfort subjects affected / exposed occurrences (all)	3 / 84 (3.57%) 3	0 / 86 (0.00%) 3	0 / 83 (0.00%) 3
Eye disorders Eye irritation subjects affected / exposed occurrences (all)	0 / 84 (0.00%) 1	0 / 86 (0.00%) 1	1 / 83 (1.20%) 1
Gastrointestinal disorders Dry mouth subjects affected / exposed occurrences (all)  Nausea subjects affected / exposed occurrences (all)  Vomiting subjects affected / exposed occurrences (all)	1 / 84 (1.19%) 1  1 / 84 (1.19%) 1  0 / 84 (0.00%) 1	0 / 86 (0.00%) 1  0 / 86 (0.00%) 1  1 / 86 (1.16%) 1	0 / 83 (0.00%) 1  0 / 83 (0.00%) 1  0 / 83 (0.00%) 1
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)  Epistaxis subjects affected / exposed occurrences (all)  Nasopharyngitis subjects affected / exposed occurrences (all)  Pharyngitis subjects affected / exposed occurrences (all)	3 / 84 (3.57%) 7  0 / 84 (0.00%) 2  0 / 84 (0.00%) 1  0 / 84 (0.00%) 1	4 / 86 (4.65%) 7  1 / 86 (1.16%) 2  1 / 86 (1.16%) 1  1 / 86 (1.16%) 1	0 / 83 (0.00%) 0  1 / 83 (1.20%) 2  0 / 83 (0.00%) 1  0 / 83 (0.00%) 1
Infections and infestations			

Herpes simplex subjects affected / exposed occurrences (all)	1 / 84 (1.19%) 1	0 / 86 (0.00%) 1	0 / 83 (0.00%) 1
--	---------------------	---------------------	---------------------

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported